Tolerability and Pharmacokinetic Study of Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-04

Study Completion Date

2016-10-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to evaluate the local tolerability of the new Econazole/Benzydamine pessary, in comparison with Econazole and Benzydamine stand-alone products and placebo. Pharmacokinetics of the study products after single and multiple applications o.d. for 3 days, overall local and general tolerability, safety and comfort of use will also be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tolerability and Pharmacokinetic Study of Econazole Nitrate and Benzydamine HCl Intravaginal Cream

NCT02713893

Healthy

COMPLETED PHASE1

Study Evaluating the Efficacy and Safety of Miconazole Nitrate + Domiphen Bromide Vaginal Cream in the Treatment of Subjects With Acute Vulvovaginal Candidiasis

NCT04813822

Acute Vulvovaginal Candidiasis

UNKNOWN PHASE2

Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis

NCT03129321

Tinea Pedis

COMPLETED PHASE3

Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.

NCT02713139

Sexual Active Women Vaginal Discharge

WITHDRAWN PHASE3

Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis

NCT00803738

Vulvovaginal Candidiasis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Women

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Econazole nitrate 150 mg plus Benzydamine HCl 6 mg

One vaginal pessary (2.7 g) of Econazole nitrate 150 mg plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days

Group Type EXPERIMENTAL

Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary

Intervention Type DRUG

Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary

Placebo plus Econazole nitrate 150 mg

One vaginal pessary (2,7 g) of Placebo plus Econazole nitrate 150 mg, once daily, for 3 consecutive days

Group Type ACTIVE_COMPARATOR

Placebo plus Econazole nitrate 150 mg vaginal pessary

Intervention Type DRUG

Placebo plus Benzydamine HCl 6 mg

One vaginal pessary (2,7 g) of Placebo plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days

Group Type ACTIVE_COMPARATOR

Placebo plus Benzydamine HCl 6 mg vaginal pessary

Intervention Type DRUG

Placebo

One vaginal pessary (2.7 g) of Placebo, once daily, for 3 consecutive days

Group Type PLACEBO_COMPARATOR

Placebo vaginal pessary

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary

Intervention Type DRUG

Placebo plus Econazole nitrate 150 mg vaginal pessary

Intervention Type DRUG

Placebo plus Benzydamine HCl 6 mg vaginal pessary

Intervention Type DRUG

Placebo vaginal pessary

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed consent: signed written informed consent before inclusion in the study.
2. Sex and age: healthy women, aged 18-55 years old inclusive.
3. Body Mass Index (BMI): 18.5-30 kg/m2 inclusive.
4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest (sitting position).
5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study.
6. Sexual abstinence: agreement to sexual abstinence during the study.

1. hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit;
2. a non-hormonal intrauterine device \[IUD\] for at least 2 months before the screening visit;
3. a male sexual partner who agrees to use a male condom;
4. a vasectomised sexual partner. Female participants of non-child-bearing potential will be admitted. For all female subjects, pregnancy test result must be negative at screening and on day 1.
8. PAP test: negative PAP test result (i.e. normal PAP test result without atypical cells) at screening.

Exclusion Criteria

1. ECG (12-leads, supine position): clinically significant abnormalities.
2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study as judged by the Investigator.
3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness.
4. Allergies: ascertained or presumptive hypersensitivity (including allergies) to the active ingredients (econazole nitrate and/or benzydamine HCl) and/or formulations' excipients or related drugs, e.g. other azoles; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study.
5. Diseases: relevant history of renal, hepatic, gastrointestinal, genitourinary, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study or affect the subject's safety.
6. Genitourinary diseases: presence of any specific genitourinary symptoms detected at visit 2 with the relevant questionnaire (genitourinary symptoms questionnaire).
7. Infection history: history of bacterial urinary tract or bacterial or fungal vaginal infections for 3 weeks before the screening visit.
8. Systemic and/or local infections: bacterial or fungal infections that may interfere with the aim of the study or affect the subject's safety. If the results of the microbiological analyses concerning Ureaplasma/Mycoplasma and Actinomyces are positive, the subject can be enrolled only if asymptomatic and without any clinical evidence (gynaecological visit, PAP test and vaginal pH measurement) of vaginal infections.
9. Gynaecological findings: clinically significant abnormal findings at the gynaecological visit performed by the study Gynaecologist.
10. Mucosa conditions: altered mucosa conditions affecting the site of insertion (e.g. open lesions or other).
11. Habits: use of vaginal detergents, soaps and washes that, in the Investigator's opinion, may have an influence on vaginal pH and/or change the vaginal flora.
12. Medications: any medication (topical or systemic), including over the counter, herbal medication, topical drugs on the application area, and anticoagulants, such as warfarin, acenocoumarol and rivaroxaban, for 2 weeks before the start of the study. Hormonal contraceptives and hormonal replacement therapies are allowed. Paracetamol will be allowed as a counter-measure for adverse events, on a case by case basis, if deemed appropriate by the Investigator.
13. Investigative drug studies: participation in the evaluation of any drug for 3 months before this study, calculated from the first day of the month following the last visit of a previous study and the first day of the present study (date of the informed consent signature).
14. Blood donation: blood donations for 3 months before this study.
15. Drug, alcohol, caffeine, tobacco: history of drug, alcohol (\> 1 drink/day, defined according to USDA Dietary Guidelines 2010), tobacco (≥ 10 cigarettes/day) or caffeine (\> 5 cups coffee/tea/day) abuse.
16. Diet: Abnormal diets (\< 1600 or \> 3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians.
17. Pregnancy: positive or missing pregnancy test at screening or day 1, pregnant or lactating women or females of child-bearing potential not following adequate contraceptive procedures.
18. Non-compliance: subjects suspected to have a high potential for non-compliance to the study procedures according to the Investigator's judgement, including non-compliance to sexual abstinence during the study.
19. Drug test (cocaine, amphetamine, methamphetamine, cannabinoids, opiates and ecstasy): positive result at the drug test at screening.
20. Alcohol test: positive alcohol breath test at day 1.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes